Trinity Biotech
TRIB
#11083
Rank
โ‚น0.41 B
Marketcap
โ‚น511.85
Share price
-4.39%
Change (1 day)
514.37%
Change (1 year)

P/E ratio for Trinity Biotech (TRIB)

P/E ratio as of November 2026 (TTM): -0.0889

According to Trinity Biotech 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.088918. At the end of 2022 the company had a P/E ratio of -0.7710.

P/E ratio history for Trinity Biotech from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-0.7710-102.29%
202133.7-369.46%
2020-12.51586.44%
2019-0.7422-65.74%
2018-2.17-18.82%
2017-2.6770.5%
2016-1.57-112.46%
201512.6-45.75%
201423.2-59.28%
201356.9226.99%
201217.426.31%
201113.8344.26%
20103.10-57.03%
20097.21-1573.52%
2008-0.4896-90.55%
2007-5.18-112.33%
200642.0202.72%
200513.986.22%
20047.45-31.46%
200310.9286.59%
20022.81-77.06%
200112.3

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Abbott Laboratories
ABT
40.6-45,815.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
36.6-41,245.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Danaher
DHR
37.6-42,411.46%๐Ÿ‡บ๐Ÿ‡ธ USA
QuidelOrtho
QDEL
-0.6944 680.89%๐Ÿ‡บ๐Ÿ‡ธ USA
OraSure Technologies
OSUR
-4.99 5,506.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Chembio Diagnostics
CEMI
-0.3792 326.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Rad Laboratories
BIO
45.8-51,615.67%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.